Seven of sixteen MDM2-positive ameloblastomas (43.75%) were BRAFV600E positive (Figure 2C), two showed weak/ambiguous staining and were considered as negative, and seven were BRAFV600E negative. Here, MDM2 is linked to ameloblastoma.